Post Acute COVID-19 Syndrome
10
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Effects of Immulina TM Supplements With PASC Patients
AT1001 for the Treatment of Long COVID
Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
Gender Differences in the Recovery Rate Following PR in Patients With Long COVID-19
Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors
Stellate Ganglion Block to Treat Long COVID 19 Case Series
Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.